The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework
This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
-Pharmacogenetic tests have not made it into the treatment or assessment process for most physicians. -Until the cost for these tests become negligible -- or, included in the cost of a particular antidepressant -- psychopharmacogenetic testing will not make it into the mainstream.
“Personalized medical diagnositics” looks to be evolving as a high impact area in neuropsychiatric drug development. Such ‘genetic biomarker’ platforms, based on either pharmacogenetic profiles coming from DNA blueprints or gene products from a simple blood draw, aim to identify patients who are...
We do not know enough about the effects of statins over a lifetime to justify use in children. Maybe we would reduce cardiovascular mortality, maybe not. But at what cost? I'm talking about both financial costs and the health costs related to drug side effects. We need a lot more information...
‘One drug, many uses’ can make lots of sense clinically and commercially. Seeking additional FDA indications for a specific drug has obvious business benefits: greater revenue stream, improved branding, potentially longer market exclusivity, greater franchising potential of the drug...
Pain is a complex of the personal, subjective, and unpleasant experiences that may or may not be related to physical injury or tissue damage. It has been described “timeless, ineluctable, and disconcertingly indefinable.” The expression may be influenced by psychosocial, ...
Lundbeck has now disclosed the mechanism of action of its “mixed serotonin modulator and stimulator,” albeit buried in a first quarter report. Data on LuAA21004, Lundbeck’s lead antidepressant jointly in development with Takeda, was released at the Scandinavian College of Neuro-Psychopharmacology...
We need to look to the cause of why we prescribe antipsychotics to patients with dementia. We have very few tools to use and sometimes these drugs are a necessity.
Medications used for realistic indications and with clinically appropriate symptomatic targets are indicated and provide effectiveness that additional staff cannot offer. Decision making in health care is too often made by those who do not really provide clinical service but provide arm chair...